[go: up one dir, main page]

AR043157A1 - Compuestos de amida tri (ciclo) substituidos - Google Patents

Compuestos de amida tri (ciclo) substituidos

Info

Publication number
AR043157A1
AR043157A1 ARP040100429A ARP040100429A AR043157A1 AR 043157 A1 AR043157 A1 AR 043157A1 AR P040100429 A ARP040100429 A AR P040100429A AR P040100429 A ARP040100429 A AR P040100429A AR 043157 A1 AR043157 A1 AR 043157A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
heteroaryl
cyano
hydroxy
Prior art date
Application number
ARP040100429A
Other languages
English (en)
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of AR043157A1 publication Critical patent/AR043157A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se presentan compuestos, proceso de obtención de los mismos y sus sales aceptables para uso farmacéutico, que son útiles en el tratamiento profiláctico y terapéutico de la hiperglucemia y diabetes. Reivindicación 1: Un compuesto de fórmula (1) o una sal aceptable para uso farmacéutico del mismo, en el cual: Q es un arilo, un anillo heteroarilo de 5 o 6 miembros o un anillo heterocíclico de 4 a 8 miembros; T junto con el -N=C- al cual se encuentra unido forman un anillo heteroarilo o un anillo heterocíclico en el que el enlace N=C es el único sitio de insaturación; R1 y R2 son, independientemente el uno del otro, H, hidroxi, halógeno, ciano, nitro, vinilo, etinilo, metoxi, OCFnH3-n, -N(alquilo C0-4)(alquilo C0-4), CHO o alquilo C1-2 opcionalmente sustituido con 1 a 5 sustituyentes independientes halógeno, hidroxi, ciano, metoxi, -N(alquilo C0-2)(alquilo C0-2), SOCH3 o SO2CH3; o R1 y R2 juntos forman un anillo carbocíclico o heterocíclico; o bien R1 y R2 pueden tomarse conjuntamente para representar un átomo de O unido al anillo por medio de un enlace doble; R3 y R4 son, independientemente el uno del otro, H, halógeno, OCFnH3-n, metoxi, CO2R77, ciano, nitro, CHO, CONR99R100, CON(OCH3)CH3 o alquilo C1-2, heteroarilo o cicloalquilo C3-7 opcionalmente sustituido con 1 a 5 sustituyentes independientes halógeno, hidroxi, ciano, metoxi, -NHCO2CH3 o -N(alquilo C0-2)(alquilo C0-2); o R3 y R4 juntos forman un anillo aromático, heteroaromático, carbocíclico o heterocíclico de 5 a 8 miembros; R5 y R6 son, independientemente el uno del otro, H, hidroxi, halógeno, ciano, nitro, CO2R7, CHO, COR8, C(OH)R7R8, C(=NOR7)R8, CONR9R10, SR7, SOR8, SO2R8, SO2NR9R10, CH2NR9R10, NR9R10, N(alquilo C0-4)SO2R8, NHCOR7, o un grupo alquilo C1-4, un grupo alquenilo C2-4, un grupo alquinilo C2-4, un grupo alcoxi C1-4, un grupo arilo o un grupo heteroarilo, en donde cualquiera de los grupos está opcionalmente sustituido con 1 a 6 sustituyentes independientes halógeno, ciano, nitro, hidroxi, alcoxi C1-2, -N(alquilo C0-2)(alquilo C0-2), alquilo C1-2, CFnH3-n, arilo, heteroarilo, -COalquilo C1-2, -CON(alquilo C0-2)(alquilo C0-2), SCH3, SOCH3, SO2CH3 o -SO2N(alquilo C0-2)(alquilo C0-2); o R5 y R6 juntos forman un anillo carbocíclico o heterocíclico de 5 a 8 miembros; R7 y R77 son, independientemente el uno del otro, son H o un grupo alquilo C1-4, un grupo alquenilo C2-4, un grupo alquinilo C2-4, un grupo cicloalquilo C3-7, un grupo arilo, un grupo heteroarilo o un grupo heterocíclico de 4 a 7 miembros, en donde cualquiera de los grupos está opcionalmente sustituido con 1 a 6 sustituyentes independientes halógeno, ciano, nitro, hidroxi, alcoxi C1-2, -N(alquilo C0-2)(alquilo C0-2), alquilo C1-2, cicloalquilo C3-7, anillo heterocíclico de 4 a 7 miembros, CFnH3-n, arilo, heteroarilo, CO2H, -COalquilo C1-2, -CON(alquilo C0-2)(alquilo C0-2), SOCH3, SO2CH3, o -SO2N(alquilo C0-2)(alquilo C0-2); R8 es un grupo alquilo C1-4, un grupo alquenilo C2-4, un grupo alquinilo C2-4, un grupo cicloalquilo C3-7, un grupo arilo, un grupo heteroarilo o un grupo heterocíclico de 4 a 7 miembros, en donde cualquiera de los grupos está opcionalmente sustituido con 1 a 6 sustituyentes independientes halógeno, ciano, nitro, hidroxi, alcoxi C1-2, -N(alquilo C0-2)(alquilo C0-2), alquilo C1-2, cicloalquilo C3-7, anillo heterocíclico de 4 a 7 miembros, CFnH3-n, arilo, heteroarilo, CO2H, COalquilo C1-2, -CON(alquilo C0-2)(alquilo C0-2), SOCH3, SO2CH3 o -SO2N(alquilo C0-2)(alquilo C0-2); R9, R10, R99 y R100 son, independientemente el uno del otro, H o un grupo alquilo C1-4, un grupo cicloalquilo C3-7, un grupo arilo, un grupo heteroarilo o un grupo heterocíclico de 4 a 7 miembros, en donde cualquiera de los grupos está opcionalmente sustituidos con 1 a 6 sustituyentes independientes halógeno, ciano, nitro, hidroxi, alcoxi C1-2, -N(alquilo C0-2)(alquilo C0-2), alquilo C1-2, cicloalquilo C3-7, anillo de 4 a 7 miembros, CFnH3-n, arilo, heteroarilo, COalquilo C1-2, -CON(alquilo C0-2)(alquilo C0-2),SOCH3, SO2CH3 o -SO2N(alquilo C0-2)(alquilo C0-2); o R9 y R10 o R99 y R100 juntos forman un sistema anular heterobicíclico de 6 a 8 miembros o un anillo heterocíclico de 4 a 8 miembros opcionalmente sustituido con 1 o 2 sustituyentes independientes alquilo C1-2, CH2OCH3, COalquilo C0-2, hidroxi o SO2CH3; n es 1, 2 o 3; m es 0 o 1; y la línea de puntos junto con la línea llena forman un enlace doble opcional y ? indica que el enlace doble posee configuración (E).
ARP040100429A 2003-02-11 2004-02-11 Compuestos de amida tri (ciclo) substituidos AR043157A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44668303P 2003-02-11 2003-02-11
US49443403P 2003-08-11 2003-08-11
US51280003P 2003-10-20 2003-10-20

Publications (1)

Publication Number Publication Date
AR043157A1 true AR043157A1 (es) 2005-07-20

Family

ID=32872762

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100429A AR043157A1 (es) 2003-02-11 2004-02-11 Compuestos de amida tri (ciclo) substituidos

Country Status (26)

Country Link
US (2) US7214681B2 (es)
EP (2) EP1594867B1 (es)
JP (1) JP4757188B2 (es)
KR (1) KR101120916B1 (es)
AR (1) AR043157A1 (es)
AT (1) ATE391718T1 (es)
AU (1) AU2004212500B2 (es)
BR (1) BRPI0407139A (es)
CA (1) CA2515670A1 (es)
CY (1) CY1110254T1 (es)
DE (1) DE602004012969T2 (es)
DK (1) DK1594867T3 (es)
EA (1) EA012700B1 (es)
ES (1) ES2303628T3 (es)
HR (1) HRP20050687A2 (es)
IL (1) IL169954A (es)
MA (1) MA27708A1 (es)
MX (1) MXPA05008406A (es)
MY (1) MY145590A (es)
NO (1) NO20053742L (es)
NZ (1) NZ541759A (es)
PL (1) PL378117A1 (es)
PT (1) PT1594867E (es)
SI (1) SI1594867T1 (es)
TW (1) TWI314553B (es)
WO (1) WO2004072031A2 (es)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
RU2005113713A (ru) * 2002-10-03 2006-01-20 Новартис АГ (CH) Замещенные (тиазол-2-ил)амиды или сульфонамиды в качестве активаторов глюкокиназы, которые могут применяться при лечении диабета типа 2
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
CA2560689C (en) 2004-04-02 2011-03-01 Novartis Ag Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful in the treatment of type 2 diabetes
JP2007530631A (ja) * 2004-04-02 2007-11-01 ノバルティス アクチエンゲゼルシャフト チアゾロピリジン誘導体、それを含む医薬組成物およびグルコキナーゼ介在性状態の処置法
CA2563192A1 (en) * 2004-04-21 2005-11-03 Prosidion Limited Tri(cyclo) substituted amide compounds
GB0418058D0 (en) * 2004-08-12 2004-09-15 Prosidion Ltd Fluorination process
US7745491B2 (en) * 2004-08-12 2010-06-29 Prosidion Limited Substituted phenylacetamides and their use as glucokinase activators
GB0418046D0 (en) * 2004-08-12 2004-09-15 Prosidion Ltd Eantioselective process
EP1910290A2 (en) 2005-06-30 2008-04-16 Prosidion Limited Gpcr agonists
KR20110084339A (ko) 2005-07-09 2011-07-21 아스트라제네카 아베 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한 헤테로아릴 벤즈아미드 유도체
TWI359149B (en) 2005-07-11 2012-03-01 Mitsubishi Tanabe Pharma Corp An oxime derivative and preparations thereof
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
JP2009509988A (ja) 2005-09-29 2009-03-12 サノフィ−アベンティス フェニル−及びピリジニル−１，２，４−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
BRPI0618062A2 (pt) * 2005-11-03 2011-08-16 Prosidion Ltd composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto
JP2009514836A (ja) * 2005-11-03 2009-04-09 プロシディオン・リミテッド トリシクロ置換型アミド
US20080293741A1 (en) * 2005-11-03 2008-11-27 Matthew Colin Thor Fyfe Tricyclo Substituted Amides as Glucokinase Modulators
US20070197532A1 (en) * 2005-11-18 2007-08-23 Cao Sheldon X Glucokinase activators
JP5236499B2 (ja) * 2006-01-27 2013-07-17 アレイ バイオファーマ、インコーポレイテッド グルコキナーゼ活性化剤
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
JP5386350B2 (ja) 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
US7888504B2 (en) * 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
EP2261216A3 (en) * 2006-07-24 2011-12-14 F. Hoffmann-La Roche AG Pyrazoles as glucokinase activators
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
DE102006047617B4 (de) * 2006-10-09 2008-11-27 Clariant International Limited Verfahren zur Herstellung basischer (Meth)acrylamide
MX2009003850A (es) 2006-10-09 2009-04-23 Clariant Finance Bvi Ltd Metodo para producir alcanol amidas de acido graso.
DE102006047620B4 (de) 2006-10-09 2008-11-27 Clariant International Limited Verfahren zur Herstellung tertiärer Amide von Alkylphenylcarbonsäuren
DE102006047618B3 (de) 2006-10-09 2007-11-15 Clariant International Limited Verfahren zur Herstellung von Bisbenzoxazolen
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
TW200831081A (en) 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
EP2105435A4 (en) * 2007-01-10 2011-06-15 Mitsubishi Tanabe Pharma Corp Hydrazone derivative
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2116533B1 (en) * 2007-03-07 2013-07-10 Kyorin Pharmaceutical Co., Ltd. Glucokinase activator
WO2008116107A2 (en) 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AR070107A1 (es) * 2008-01-15 2010-03-17 Lilly Co Eli R-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida en forma cristalina, composicion farmaceutica que la comprende y su uso para la manufactura de un medicamento util para la prevencion o tratamiento de hiperglicemia
US8329707B2 (en) * 2008-01-18 2012-12-11 Astellas Pharma Inc. Substituted pyrazine compounds
DE102008017216B4 (de) 2008-04-04 2013-08-14 Clariant International Ltd. Kontinuierliches Verfahren zur Herstellung von Fettsäureamiden
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
HUE025224T2 (en) 2008-04-28 2016-02-29 Kyorin Seiyaku Kk Ciklopentilakrilsav amide derivatives
WO2009139438A1 (ja) * 2008-05-15 2009-11-19 田辺三菱製薬株式会社 光学活性カルボン酸の製造方法
US8563730B2 (en) 2008-05-16 2013-10-22 Takeda San Diego, Inc. Pyrazole and fused pyrazole glucokinase activators
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
UA104742C2 (uk) 2008-12-19 2014-03-11 Эли Лилли Энд Компани Похідні арилциклопропілацетаміду, застосовні як активатори глюкокінази
DE102009031059A1 (de) 2009-06-30 2011-01-05 Clariant International Ltd. Vorrichtung zur kontinuierlichen Durchführung chemischer Reaktionen bei hohen Temperaturen
BR112012003973A2 (pt) 2009-08-26 2015-09-08 Sanofi Sa hidratos de fluoroglicosídeo heteroaromático cristalinos, produtos farmacêuticos compreendendo estes compostos e seu uso
DE102009042522A1 (de) 2009-09-22 2011-04-07 Clariant International Ltd. Kontinuierliches Umesterungsverfahren
DE102009042523B4 (de) 2009-09-22 2012-02-16 Clariant International Ltd. Vorrichtung und Verfahren zur kontinuierlichen Durchführung heterogen katalysierter chemischer Reaktionen bei hohen Temperaturen
WO2011058193A1 (en) 2009-11-16 2011-05-19 Mellitech [1,5]-diazocin derivatives
US8222416B2 (en) 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
EP2402327B1 (en) 2010-06-29 2018-03-07 Impetis Biosciences Ltd. Acetamide compounds as glucokinase activators, their process and medicinal applications
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
US8877794B2 (en) * 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
EP2627654A1 (en) 2010-10-13 2013-08-21 Takeda California, Inc. Method of making azaindazole derivatives
DE102010056565A1 (de) 2010-12-30 2012-07-05 Clariant International Ltd. Verfahren zur Modifizierung Hydroxylgruppen tragender Polymere
DE102010056564A1 (de) 2010-12-30 2012-07-05 Clariant International Limited Hydroxylgruppen und Estergruppen tragende Polymere und Verfahren zu ihrer Herstellung
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6218736B2 (ja) 2012-09-26 2017-10-25 興和株式会社 新規なフェニルアセトアミド化合物、及びそれを含有する医薬

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US320050A (en) * 1885-06-16 Geoege t
US219887A (en) * 1879-09-23 Improvement in wooden printing-types
US4046768A (en) * 1976-06-17 1977-09-06 Velsicol Chemical Corporation 1-Thiazolyl-5-pyridylcarbonyloxyimidazolidinones
ES2226811T3 (es) * 1999-03-29 2005-04-01 F. Hoffmann-La Roche Ag Activadores de glucoquinasa.
US6610846B1 (en) 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
HUP0203542A3 (en) * 1999-08-12 2003-07-28 Upjohn Co 3(5)-amino-pyrazole derivatives, process for their preparation, their use and pharmaceutical compositions containing the same
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
CA2407416C (en) 2000-05-03 2006-07-18 Paige Erin Mahaney Alkynyl phenyl heteroaromatic glucokinase activators
DE60113247T2 (de) 2000-05-03 2006-06-22 F. Hoffmann-La Roche Ag Hydantoin-enthaltende glucokinase aktivatoren
ATE280163T1 (de) 2000-05-08 2004-11-15 Hoffmann La Roche Substituierte phenylacetamide und ihre verwendung als glukokinase aktivatoren
BR0110703A (pt) * 2000-05-08 2003-01-28 Hoffmann La Roche Amida, composição farmacêutica que compreende um composto, compostos, utilização de compostos, processos para o tratamento profilático ou terapêutico de diabetes do tipo ii e para a preparação desses compostos
US6489485B2 (en) 2000-05-08 2002-12-03 Hoffmann-La Roche Inc. Para-amine substituted phenylamide glucokinase activators
DE60111534T2 (de) 2000-07-20 2006-05-11 F. Hoffmann-La Roche Ag Alpha-acyl- und alpha-heteroatom-substituierte benzenacetamide verwendbar als glucokinase-aktivatoren
US6369232B1 (en) 2000-08-15 2002-04-09 Hoffmann-La Roche Inc. Tetrazolyl-phenyl acetamide glucokinase activators
JP4109111B2 (ja) * 2000-12-06 2008-07-02 エフ．ホフマン−ラ ロシュ アーゲー 縮合複素環式芳香族グルコキナーゼアクチベーター
US6433188B1 (en) 2000-12-06 2002-08-13 Wendy Lea Corbett Fused heteroaromatic glucokinase activators
US6482951B2 (en) 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
SE0102300D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
AU2002349299A1 (en) 2001-12-03 2003-06-17 Novo Nordisk A/S Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
US6911545B2 (en) 2001-12-19 2005-06-28 Hoffman-La Roche Inc. Crystals of glucokinase and methods of growing them
US20030171411A1 (en) 2001-12-21 2003-09-11 Kodra Janos Tibor Amide derivatives as therapeutic agents
JP4419571B2 (ja) 2002-03-26 2010-02-24 萬有製薬株式会社 新規アミノベンズアミド誘導体
AU2003232204B8 (en) 2002-04-26 2009-07-30 F. Hoffmann-La Roche Ag Substituted phenylacetamides and their use as glucokinase activators
EP1518925A4 (en) 2002-05-16 2006-01-04 Banyu Pharma Co Ltd GLUCOKINASE PROTEIN CRYSTAL AND METHOD FOR THE DRUG CONSTRUCTION USING THE CRYSTAL
EP1531815B1 (en) 2002-06-27 2014-09-24 Novo Nordisk A/S Glucokinase activators
RU2005113713A (ru) 2002-10-03 2006-01-20 Новартис АГ (CH) Замещенные (тиазол-2-ил)амиды или сульфонамиды в качестве активаторов глюкокиназы, которые могут применяться при лечении диабета типа 2
WO2004063179A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Substituted arylcyclopropylacetamides as glucokinase activators

Also Published As

Publication number Publication date
EA012700B1 (ru) 2009-12-30
NO20053742L (no) 2005-08-29
PT1594867E (pt) 2008-06-03
HRP20050687A2 (en) 2006-02-28
IL169954A (en) 2010-12-30
EA200501095A1 (ru) 2006-04-28
WO2004072031A2 (en) 2004-08-26
TWI314553B (en) 2009-09-11
AU2004212500B2 (en) 2010-06-24
CA2515670A1 (en) 2004-08-26
SI1594867T1 (sl) 2008-10-31
US7582632B2 (en) 2009-09-01
KR20060058049A (ko) 2006-05-29
EP1594867A2 (en) 2005-11-16
DK1594867T3 (da) 2008-07-21
WO2004072031A3 (en) 2004-12-02
DE602004012969T2 (de) 2009-06-18
AU2004212500A1 (en) 2004-08-26
US20040181067A1 (en) 2004-09-16
DE602004012969D1 (de) 2008-05-21
CY1110254T1 (el) 2015-01-14
ATE391718T1 (de) 2008-04-15
EP2168962A2 (en) 2010-03-31
NZ541759A (en) 2009-02-28
MXPA05008406A (es) 2006-02-17
MY145590A (en) 2012-02-29
US7214681B2 (en) 2007-05-08
EP2168962A3 (en) 2010-04-07
WO2004072031A8 (en) 2005-10-06
BRPI0407139A (pt) 2006-02-07
ES2303628T3 (es) 2008-08-16
MA27708A1 (fr) 2006-01-02
PL378117A1 (pl) 2006-03-06
TW200505881A (en) 2005-02-16
EP1594867B1 (en) 2008-04-09
JP4757188B2 (ja) 2011-08-24
JP2006517590A (ja) 2006-07-27
KR101120916B1 (ko) 2012-04-12
US20070281946A1 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
AR043157A1 (es) Compuestos de amida tri (ciclo) substituidos
AR043158A1 (es) Compuestos activadores de glucoquinasa de amida tri(ciclo) sustituidos, procedimientos para su preparacion y composiciones farmaceuticas que los contienen
AR088226A1 (es) Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas
CO6290657A2 (es) Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-alfa]piridinas su preparacion y su aplicacion en terapeutica
AR076264A1 (es) Triazolopiridinas sustituidas y analogos de estas
AR096979A1 (es) Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR087328A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
AR074596A1 (es) Derivados de (3-oxo) piridazin-4-ilurea
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
CO5721006A2 (es) Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa
AR043508A1 (es) 1-amino 1-h-imidazoquinolinas y su uso como inmunomoduladores
CO6341631A2 (es) Derivados de 1,2,4 - oxadiazol y su uso terapéutico
AR049331A1 (es) Derivados de imidazopiridinas, imidazoquinolinas e iimidazonaftiridinas sustituidas con amidas como moduladores de biosintesis de citoquinas. composiciones farmaceuticas.
AR082886A1 (es) Compuestos y composiciones farmaceuticas que los contienen
AR045261A1 (es) Compuestos que contienen imidazo quinolina o imidazo piridina sustituidos; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos inmunomoduladores
CO5590895A2 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos
AR067762A1 (es) Proceso para preparar 5-fluoro-1h-pirazolo (3,4-b) piridin-3-amina y derivados de la misma
AR045529A1 (es) Imidazoquinolinas sustituidas con grupos ariloxi o arilalquilenoxi
AR007253A1 (es) Derivados de pirimidina o sus sales y n-oxidos farmaceuticamente aceptables composicion farmaceutica que los contiene, procedimiento para preparar a dichosderivados y metodo para la preparacion de una composicion farmaceutica conteniendo a uno de dichos derivados
PE20200664A1 (es) Compuestos espirociclicos y sus metodos de preparacion y uso
AR048567A1 (es) Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas.
AR044342A1 (es) Derivados de bencimidazol
ECSP045278A (es) Compuestos de oxo-azabicíclicos
AR039988A1 (es) Derivados de benzoxazina como moduladores de 5-ht6 y usos de los mismos
EA201171385A1 (ru) Производные циклопента[с]пирролилалкилкарбаматов 5-членных гетероциклов, способ их получения и применение их в терапии

Legal Events

Date Code Title Description
FA Abandonment or withdrawal